JMP reiterates Market Outperform rating on AtriCure stock after strong Q2

Published 30/07/2025, 09:58
JMP reiterates Market Outperform rating on AtriCure stock after strong Q2

Investing.com - JMP Securities has reiterated its Market Outperform rating and $60.00 price target on AtriCure Inc. (NASDAQ:ATRC), a $1.57 billion market cap medical device company, following the company’s second-quarter 2025 financial results, which exceeded analyst expectations. According to InvestingPro data, the stock has shown significant momentum with a 2.95% return over the past week.

AtriCure reported quarterly sales growth of 17% year-over-year, outpacing consensus and JMP’s estimate by approximately 5%, maintaining its strong revenue growth trajectory of 15.79% over the last twelve months. The company’s adjusted EBITDA nearly doubled year-over-year to $15.4 million, significantly exceeding the Street’s expectation of $10 million. The company maintains a healthy financial position with a current ratio of 4.11, indicating strong liquidity.

The strong performance was driven by impressive growth across AtriCure’s business segments, with Pain Management increasing 43% year-over-year and Appendage Management growing 20% year-over-year. These results reflect increased momentum from recent product launches.

AtriCure’s Open Ablation division also contributed to the positive results with 17% year-over-year growth, benefiting from continued adoption of its flagship product, EnCompass. Sales from all three business segments showed top-line acceleration compared to the first quarter of 2025.

Following these results, AtriCure raised both its top-line and bottom-line guidance for the remainder of the year, according to JMP Securities.

In other recent news, AtriCure Inc reported its second-quarter 2025 earnings, revealing a performance that exceeded market expectations. The company posted an earnings per share (EPS) of -$0.13, which was better than the anticipated -$0.17. This marks a 23.53% positive surprise for investors. Additionally, AtriCure’s revenue reached $136.1 million, surpassing forecasts of $130.17 million. These results indicate a strong quarter for the company, reflecting positively on its financial management strategies. The company’s recent performance has garnered attention from analysts and investors alike. The earnings announcement has been a focal point for market participants. There were no analyst upgrades or downgrades reported in this period.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.